Seeking Alpha

Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical...

Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical tests of its INX-189 hepatitis C treatment and saying it plans to expand its testing to evaluate the effect of various doses. The company notes it will use the proceeds from a 1.9M common stock offering to help support its INHX-189 development in 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|